

Board of Directors - Public

SUMMARY

Meeting Date: 26 January 2022

Agenda Item: 14

| | | |
|---|--|---------------------------------|
| Report Title: | Financial Performance Report | |
| Author(s): | Matt White, Deputy Director of Finance | |
| Accountable Director: | Phillip Easthope, Executive Director of Finance, IMST & Performance | |
| Other Meetings presented to or previously agreed at: | Committee/Group: | Finance & Performance Committee |
| | Date: | 13 January 2022 |
| Key Points recommendations to or previously agreed at: | Routine reporting of financial performance. Currently no major risks or concerns other than the continued need to identify CIPs. Non-recurrent underspends to date driven by reduced Covid-19 Costs and delays in recruitment linked to MHIS investment and expansion. | |

Summary of key points in report

Summary at November 2021:

- The Organisation wide surplus of £2.3m at the end of M8 (Nov 21), £300k favourable to plan. The organisation continues to spend greater amounts in H2 than H1, there has been no further underspends on the H1 outturn position of £2.3m.
- Further non-recurrent spending plans have been approved in M8 which will assist the Trust to deliver it's planned break even position.
- Further work is being carried out on the H2 income position and adjustments will be made where applicable.
- MHIS spend in M8 shows a small increase in run rate over M7 suggesting that recruitment is ongoing and new starters commencing albeit at a reduced rate than planned.
- Covid underspend is £3.2m as expected. Covid funding for H2 was confirmed at £3.3m, in line with the H1 allocation and £6.6m estimate for the year. Covid costs remain low and support an estimated £4.8m underspend at year end.
- Agency and Out of Area Costs remain high risk. Total spend to date on these areas stands at £10.4m which equates to 12% of the total organisational spend.
- Capital spend is currently underspending against plan, however a large increase in spend is anticipated in the final few months of the financial year.

| Recommendation for the Board/Committee to consider: | | | | | | |
|---|--|----------|--|-----------|---|-------------|
| Consider for Action | | Approval | | Assurance | x | Information |
| Continue to progress the identification of FY21/22 CIP (and address the Clinical CIP gap in particular) through the newly-established CIP Working Group. | | | | | | |
| Continue working up of H2 Plan refresh in advance of the NHSI timetable, identifying new cost pressures, investment opportunities, deliverable CIP, and other risks/opportunities to be managed in reaching a balanced position at the end of March 2022. | | | | | | |
| Comment from Finance & Performance Committee | | | | | | |
| Assured regarding the ongoing oversight and management of the financial position to year-end | | | | | | |

| Please identify which strategic priorities will be impacted by this report: | | | | | | | | |
|---|-----|---|----|---|---|---|--------------------------------|---|
| | | | | | Yes | X | No | |
| Covid-19 Recovering Effectively | | | | | Yes | X | No | |
| Getting Back to Good – Continuous Improvement | | | | | Yes | X | No | |
| Transformation – Changing things that will make a difference | | | | | Yes | X | No | |
| Partnerships – working together to make a bigger impact | | | | | Yes | | No | X |
| Is this report relevant to compliance with any key standards ? | | | | | | | State specific standard | |
| Care Quality Commission Fundamental Standards | Yes | X | No | | Regulation 17: Good Governance Regulation 13: Financial Position | | | |
| Data Security & Protection Toolkit | Yes | | No | X | | | | |
| Any other specific standard | Yes | | No | X | | | | |
| Have these areas been considered ? YES/NO | | | | | If Yes, what are the implications or the impact? If no, please explain why | | | |
| Service user and carer safety and Experience | Yes | | No | X | Out of scope | | | |
| Financial (revenue & capital) | Yes | X | No | | Identification of financial sustainability risks | | | |
| OD/Workforce | Yes | | No | X | Out of Scope | | | |
| Equality, Diversity & Inclusion | Yes | | No | X | | | | |
| Legal | Yes | | No | X | Out of Scope | | | |

Financial Performance Report

November 2021

| Contents | Slide/Page |
|----------------------------------|---------------------------|
| Executive Summary | <u>3</u> |
| Financial Overview | <u>4</u> |
| Forecast | <u>5</u> |
| Risk & Recovery | <u>6</u> |
| Covid | <u>7</u> |
| Cost Improvement Programme | <u>8</u> |
| Summary of Financial Position | <u>9</u> |
| 12 Months Cash Flow | <u>10</u> |
| Capital Programme | <u>11</u> |

Executive Summary

| KPI | Annual Plan £'000 | Year to Date Plan £'000 | Year To Date Actual £'000 |
|-------------------------------|-----------------------------------|----------------------------|------------------------------|
| Surplus/Deficit | 0 | 1,993 | 2,345 |
| Covid Expenditure | 6,596 | 4,397 | 1,245 |
| Agency | 5,904 | 3,790 | 4,004 |
| Cash | 62,075 | 61,772 | 63,140 |
| Efficiency Savings | 2,650 | 1,847 | 1,844 |
| Capital | 8,584 | 5,606 | 3,557 |
| Better Payments Practice Code | 99.4% by Number 99.6% by Value | | |

Summary at November 2021:

- The Organisation wide surplus of £2.3m at the end of M8 (Nov 21), £300k favourable to plan. The organisation continues to spend greater amounts in H2 than H1, there has been no further underspends on the H1 outturn position of £2.3m.
- Further non-recurrent spending plans have been approved in M8 which will assist the Trust to deliver it's planned break even position.
- Further work is being carried out on the H2 income position and adjustments will be made where applicable.
- MHIS spend in M8 shows a small increase in run rate over M7 suggesting that recruitment is ongoing and new starters commencing albeit at a reduced rate than planned.
- Covid underspend is £3.2m as expected. Covid funding for H2 was confirmed at £3.3m, in line with the H1 allocation and £6.6m estimate for the year. Covid costs remain low and support an estimated £4.8m underspend at year end.
- Agency and Out of Area Costs remain high risk. Total spend to date on these areas stands at £10.4m which equates to 12% of the total organisational spend.
- Capital spend is currently underspending against plan, however a large increase in spend is anticipated in the final few months of the financial year.


| SPC Metrics | SPC Variation | SPC Target |
|----------------|---------------|------------|
| Covid Costs | ● L ● | n/a |
| Agency Staff £ | ● H ● | F |
| Out of Area £ | ● H ● | F |

| SPC variation | |
|---------------|--|
| ● ● ● | Common cause |
| ● L ● | Improvement - where low is good |
| ● H ● | Improvement - where high is good |
| ● L ● | Concern - where high is good |
| ● H ● | Concern - where low is good |
| ● ? ● | Special cause - where neither high nor low is good |

| SPC target | |
|------------|------------------------------|
| ? | Target Indicator – Pass/Fail |
| P | Target Indicator – Pass |
| F | Target Indicator – Fail |

Financial Overview

MHIS Slippage



Summary at M8 November 2021:

- Operating **surplus of £2,345k** (£2.3m) at Month 8 (Month 7: £2,326k).
- Continued increase in non-recurrent spend has lead to minimum change between M7 and M8 financial position.
- Agency and Out of Area placements remain risks to the Organisation's underlying position. See *Risks and Recovery* slide for detail.
- Low Covid spend and underspends against investments continues to drive Trust surplus position.
- Strong cash position continues
- The Capital programme spending plan has been revised to accurately forecast spend. It remains behind schedule, albeit at a much lower rate of £73k.

Income & Expenditure Summary

| | Year to Date | | | | Forecast | | | |
|--------------------------|---------------|----------------|------------------|------|-----------------|------------------|---------------------|-----------|
| | Plan £000 | Actual £000 | Variance £000 | % | H2 Plan £000 | H2 Fcast £000 | H2 Variance £000 | % |
| Clinical Income | 82,145 | 83,544 | 1,399 | 2% | 124,260 | 125,317 | 1,057 | 1% |
| Other Income | 12,956 | 13,317 | 361 | 3% | 19,416 | 19,976 | 560 | 3% |
| Total Income | 95,101 | 96,861 | 1,760 | | 143,676 | 145,293 | 1,617 | 1% |
| Pay | 74,857 | 74,941 | (84) | (0%) | 114,592 | 114,796 | (204) | (0%) |
| Non Pay | 19,472 | 18,475 | 997 | 5% | 26,493 | 25,549 | 944 | 4% |
| Total Expenditure | 94,329 | 93,416 | 913 | | 141,085 | 140,345 | 740 | |
| Post EBITDA | 1,139 | 1,124 | 15 | 1% | 5,809 | 6,235 | (426) | (7%) |
| Surplus/Deficit | (367) | 2,321 | (2,688) | | (3,218) | (1,287) | 1,303 | |
| KPI's | | | | | | | | |
| Out of Town (OOT) | 5,940 | 6,375 | (435) | (7%) | 8,820 | 9,563 | (743) | (8%) |
| Agency | 3,790 | 4,004 | (214) | (6%) | 5,904 | 7,434 | (1,530) | (26%) |
| Covid | 4,397 | 1,245 | 3,152 | 72% | 6,596 | 1,812 | 4,784 | 73% |
| CIPs | 1,847 | 1,844 | 3 | 0% | 2,650 | 2,650 | 0 | 0% |

See right for Directorate split

Directorate Year To Date Position

| | | Trust Wide £000 | Clinical £000 | Corporate £000 | GP Surgeries £000 | Medical £000 | Central Budgets £000 | Central Reserves £000 |
|---------|--------|-----------------------|------------------|-------------------|-------------------------|-----------------|----------------------------|-----------------------------|
| Pay | Plan | 74,857 | 54,430 | 6,707 | 11,926 | 0 | 624 | 1,170 |
| | Actual | 74,941 | 56,682 | 11,203 | 7 | 6,986 | 8 | 56 |
| | Var | (84) | (2,252) | (4,497) | 11,919 | (6,986) | 616 | 1,114 |
| Non Pay | Plan | 19,472 | 9,559 | 8,537 | 0 | 1,183 | 307 | (114) |
| | Actual | 18,475 | 12,336 | 5,584 | 2 | 937 | (460) | 77 |
| | Var | 997 | (2,777) | 2,953 | (2) | 246 | 767 | (191) |



Forecast

| | Prior Year £'000 | Actual | | | | | | | | | | Forecast | | | | |
|---|---------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-------------------------------|-------------------|-------------------|
| | | Apr-21 £'000 | May-21 £'000 | Jun-21 £'000 | Jul-21 £'000 | Aug-21 £'000 | Sep-21 £'000 | Oct-21 £'000 | Nov-21 £'000 | Dec-21 £'000 | Jan-22 £'000 | Feb-22 £'000 | Mar-22 £'000 | Forecast Out-turn £'000 | M12 Plan £'000 | Variance £'000 |
| Income | | | | | | | | | | | | | | | | |
| Income from Patient Care Activities | 118,174 | 10,072 | 9,691 | 10,586 | 10,296 | 10,219 | 12,110 | 10,296 | 10,274 | 10,443 | 10,443 | 10,443 | 10,443 | 125,317 | 125,317 | 0 |
| Other Operating Income | 35,537 | 1,726 | 1,579 | 1,634 | 1,711 | 1,723 | 1,511 | 1,633 | 1,800 | 1,665 | 1,665 | 1,665 | 1,665 | 19,976 | 19,976 | 0 |
| Total Income | 153,711 | 11,798 | 11,270 | 12,220 | 12,007 | 11,942 | 13,621 | 11,929 | 12,074 | 12,108 | 12,108 | 12,108 | 12,108 | 145,293 | 145,293 | 0 |
| Expenditure | | | | | | | | | | | | | | | | |
| Substantive | 105,189 | 7,997 | 8,096 | 8,044 | 7,960 | 8,074 | 9,411 | 8,230 | 8,495 | 8,468 | 8,468 | 8,468 | 8,468 | 100,178 | 100,178 | 0 |
| Bank | 6,006 | 662 | 393 | 581 | 503 | 586 | 561 | 503 | 566 | 604 | 604 | 604 | 604 | 6,771 | 6,771 | 0 |
| Agency | 4,638 | 389 | 403 | 503 | 503 | 593 | 568 | 538 | 507 | 858 | 858 | 858 | 858 | 7,434 | 7,434 | 0 |
| Other (Apprenticeship Levy) | 411 | 38 | 39 | 39 | 38 | 39 | 13 | 34 | 35 | 35 | 35 | 35 | 35 | 413 | 413 | 0 |
| Total Pay | 116,244 | 9,086 | 8,931 | 9,167 | 9,004 | 9,292 | 10,553 | 9,305 | 9,603 | 9,964 | 9,964 | 9,964 | 9,964 | 114,796 | 114,796 | 0 |
| Purchase of Healthcare | 8,149 | 710 | 680 | 845 | 827 | 845 | 862 | 795 | 811 | 797 | 797 | 797 | 797 | 9,563 | 9,563 | 0 |
| Drugs | 850 | 75 | 75 | 74 | 83 | 76 | 90 | 73 | 80 | 78 | 78 | 78 | 78 | 939 | 939 | 0 |
| Other non pay | 18,011 | 972 | 960 | 1,271 | 1,325 | 1,162 | 1,224 | 1,383 | 1,178 | 1,393 | 1,393 | 1,393 | 1,393 | 15,047 | 15,047 | 0 |
| Total Non Pay | 27,010 | 1,757 | 1,715 | 2,190 | 2,235 | 2,083 | 2,176 | 2,251 | 2,069 | 2,268 | 2,268 | 2,268 | 2,268 | 25,549 | 25,549 | 0 |
| Total Expenditure | 143,254 | 10,843 | 10,646 | 11,357 | 11,239 | 11,375 | 12,729 | 11,556 | 11,672 | 12,232 | 12,232 | 12,232 | 12,232 | 140,345 | 140,345 | 0 |
| EBITDA | 10,457 | 955 | 624 | 863 | 768 | 567 | 892 | 373 | 402 | (124) | (124) | (124) | (124) | 4,948 | 4,948 | 0 |
| Post EBITDA | 7,827 | 395 | 395 | 395 | 389 | 388 | 389 | 386 | 386 | 778 | 778 | 778 | 778 | 6,235 | 6,235 | 0 |
| Net Surplus / (Deficit) | 2,630 | 560 | 229 | 468 | 379 | 179 | 503 | (13) | 16 | (902) | (902) | (902) | (902) | (1,287) | (1,287) | 0 |
| Technical Adjustments | 35 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 316 | 316 | 316 | 316 | 1,287 | 1,287 | 0 |
| Adjusted Net Surplus / (Deficit) | 2,665 | 563 | 232 | 471 | 382 | 182 | 506 | (10) | 19 | (586) | (586) | (586) | (586) | 0 | 0 | 0 |



Commentary:

- The Organisational surplus at M7 of £2.3m is above revised H2 plans of £2m. This is largely driven by underspends against Covid funds and Investments.
- The non-recurrent underspends are partially offset by overspends in out of area placements and temporary staffing on in-patient wards.
- The Organisation's H2 plan is for a break even position. This will involve increased expenditure in the final months of the year to offset the H1 underspend.

Risk & Recovery | Out of Area & Agency




- Out of Area:**
- YTD Spend of £6.3m (orange line adjacent graph).
 - Contracts for 12 Acute Beds in place. This increases the SHSC bed base by 8 beds, when offsetting closures due to estates work are accounted for.
 - Early signs of more stable costs (at higher level) due to contracts “fixing” costs.
 - Current levels expected to remain for duration of financial period.




- Agency:**
- YTD Spend of £4m (orange line adjacent graph)
 - Increased spend expected in the final months of the financial year against non-recurrent funds.
 - Costs remain well above the two year average level and volatile.
 - At M8 G1, Burbage and Stanage remain the top 3 cost drivers.
 - While agency use has increased over the previous 12 months it should be considered that increased investments have increased vacancies and agency staff play a vital role in helping to cover these.

Covid

2021/22 Covid Income




2021 Full Year Forecast




- There has been no reduction in Covid funds available in H2.
- Covid spend remains low and the M8 Surplus is in line with expectation at £3.2m.
- Forecast surplus for the year, at this level of spend is £4.8m. Plans required to repurpose this non recurrently to support break even position this year.
- While some Covid funds are likely to be available in 22/23, the panning guidance indicates that a separate covid funding stream will be phased out during the year.


SPC Chart – Covid Expenditure



Monthly Staff Costs



Covid Expenditure Split





Cost Improvement Programme

| Directorate | Year to Date | | | | | Forecast Outturn | | | | |
|-------------------------------|--------------|------------|--------------|--------------|---------------|------------------|------------|--------------|--------------|---------------|
| | Target | Delivery | | | Gap to Target | Target | Delivery | | | Gap to Target |
| | | R | NR | Total | | | R | NR | Total | |
| £ | £ | £ | £ | £ | £ | £ | £ | £ | £ | |
| Central Management | 20 | 20 | | 20 | | 30 | 30 | | 30 | |
| Acute & Community Services | 530 | 58 | | 58 | 472 | 795 | 87 | | 87 | 709 |
| Rehab & Specialist Services | 419 | | 627 | 628 | (209) | 628 | 1 | 627 | 628 | |
| Clinical Directorates | 969 | 78 | 627 | 705 | 263 | 1,453 | 117 | 627 | 744 | 709 |
| Medical | 25 | 25 | | 25 | | 38 | 38 | | 38 | |
| Corporate Governance | 15 | 15 | | 15 | | 23 | 23 | | 23 | |
| Special Projects & Facilities | 91 | 74 | 17 | 91 | | 136 | 111 | 26 | 136 | |
| Nursing & Professions | 35 | 35 | | 35 | | 52 | 52 | | 52 | |
| People | 33 | 11 | | 11 | 21 | 49 | 17 | | 17 | 32 |
| Finance | 57 | 76 | | 76 | (19) | 86 | 113 | | 113 | (28) |
| Corporate | 256 | 236 | 17 | 253 | 3 | 384 | 354 | 26 | 380 | 4 |
| Reserves | 542 | | 808 | 808 | (266) | 813 | | 1,526 | 1,526 | (713) |
| Grand Total | 1,767 | 314 | 1,452 | 1,767 | (0) | 2,650 | 471 | 2,179 | 2,650 | 0 |

- Areas having the most difficulty identifying long term cost reductions are Clinical areas
- Within the Acute and Community area plans have been drawn up and are progressing through governance routes.
- While in year savings have been identified and processed in Rehab and Specialist Services, it is recognised that additional work is needed to create longer term savings that support sustainability.
- Minimal change this month.

SOFP | Statement of Financial Position

| | OPENING 2021/22 | ACTUAL | MOVEMENT | YEAR END PLAN |
|--|-----------------|-----------------|--------------|-----------------|
| | £'000 | £'000 | £'000 | £'000 |
| Non-Current Assets | | | | |
| Property, Plant & Equipment (PPE) | 57,810 | 59,474 | 1,664 | 49,384 |
| Intangible Assets | 1,062 | 955 | (107) | 1,998 |
| Other Non-Current Assets | 4,554 | 4,417 | (137) | 4,617 |
| Non-Current Assets Total | 63,426 | 64,846 | 1,420 | 55,999 |
| Current Assets | | | | |
| Receivables | 3,541 | 2,736 | (805) | 7,699 |
| Cash and Cash Equivalents | 62,075 | 63,140 | 1,065 | 55,741 |
| Other Current Assets | 2,876 | 3,901 | 1,025 | 105 |
| Total Current Assets | 68,492 | 69,777 | 1,285 | 63,545 |
| Current Liabilities | | | | |
| Provisions | (613) | (449) | 164 | (704) |
| Payables | (8,580) | (6,705) | 1,875 | (10,694) |
| Other Current Liabilities | (5,204) | (6,623) | (1,419) | (29) |
| Total Current Liabilities | (14,397) | (13,777) | 620 | (11,427) |
| Net Current Assets/ (Liabilities) | 54,095 | 56,000 | 1,905 | 52,118 |
| Total Non-Current Liabilities | (6,039) | (6,014) | 25 | (5,441) |
| Total Net Assets | 111,482 | 114,832 | 3,350 | 102,676 |
| Total Taxpayers Equity | 111,482 | 114,832 | 3,350 | 102,676 |



STATEMENT OF FINANCIAL POSITION COMMENTARY

- We are reporting a positive cash position to the end of November 2021. There are no working capital concerns, no debt facilities, and we continue to meet the Better Payment Practice expectations. Our current ratio (current assets to current liabilities) was at 5:1 at the end of November 2021, with Cash contributing 91% of current assets, denoting a high level of liquidity.
- Cash flow will be supported over the next 3 years by the sale of Fulwood land
- Liabilities have remained under control for the month.

HIGHLIGHTS FOR THE REMAINDER OF THE YEAR

- The new EPR will increase intangible assets when the project commences.
- Debt remains within expected parameters.
- Disposal of Fulwood land - contract due for signature in December 2021. Income from this sale is expected over the next three years.

NET WORKING CAPITAL

- At the end of November 2021 the Organisation reports a positive cash balance of £63,140k.
- The negative working capital balance of £5,691k is a combination of an increase in receivables and decrease of payables including Tax, NI and Pension. There are higher creditors accruals than debtors for a net balance of £3,642k.
- Overall there is a positive net working capital balance including cash of £57,731k this is after meeting the negative working capital balance of £5,691k including deferred income.
- The high liquidity ratio of 5:1 will allow the Organisation to continue without the need for any working capital loan facility in the near future while progressing the 5 years Capital Programme.

12 Months Cash Flow Forecast


| | Prior Year Mar-21 £000s | Actual 2021/22 Apr-21 £000s | Actual 2021/22 May-21 £000s | Actual 2021/22 Jun-21 £000s | Actual 2021/22 Jul-21 £000s | Actual 2021/22 Aug-21 £000s | Actual 2021/22 Sep-21 £000s | Actual 2021/22 Oct-21 £000s | Forecast 2021/22 Nov-21 £000s | Forecast 2021/22 Dec-21 £000s | Forecast 2021/22 Jan-22 £000s | Forecast 2021/22 Feb-22 £000s | Forecast 2021/22 Mar-22 £000s |
|--|-------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--|--|--|--|--|
| Cash flow as at October 2021 | | | | | | | | | | | | | |
| Operating Surplus/(deficit) | 3,898 | 560 | 510 | 608 | 520 | 319 | 644 | 127 | 590 | 590 | 590 | 590 | 590 |
| Net cash generated from / (used in) operations | 9,881 | (2,196) | 748 | (1,134) | 2,737 | 1,765 | (2,302) | 2,098 | 435 | 583 | (1,717) | 140 | 220 |
| Net cash inflow/(outflow) from investing activities, Total | (5,574) | (76) | (408) | (216) | (644) | (378) | (787) | (341) | (528) | (871) | (971) | (346) | (837) |
| Net cash inflow/(outflow) before financing | 8,205 | (1,712) | 850 | (742) | 2,613 | 1,706 | (2,445) | 1,884 | 497 | 302 | (2,098) | 384 | (27) |
| Net Cash inflow/(outflow) from financing activities, Total | 2,852 | 0 | 0 | 0 | 0 | 0 | (807) | 0 | 1,029 | 0 | 0 | 285 | (846) |
| Increase/(decrease) in cash and cash equivalents | 11,057 | (1,712) | 850 | (742) | 2,613 | 1,706 | (3,252) | 1,884 | 1,526 | 302 | (2,098) | 669 | (873) |
| Cash and cash equivalents at start of period | 51,018 | 62,075 | 60,363 | 61,213 | 60,471 | 63,084 | 64,790 | 61,538 | 63,422 | 64,948 | 65,250 | 65,250 | 63,152 |
| Increase/(decrease) in cash and cash equivalents | 11,057 | (1,712) | 850 | (742) | 2,613 | 1,706 | (3,252) | 1,884 | 1,526 | 302 | (2,098) | 669 | (873) |
| Cash and cash equivalents at end of period | 62,075 | 60,363 | 61,213 | 60,471 | 63,084 | 64,790 | 61,538 | 63,422 | 64,948 | 65,250 | 63,152 | 65,919 | 62,279 |

NARRATIVE

The Organisation is expected to meet its Capital Programme target of £7,707k which has been reduced by £877k to contribute with the over committed ICS's CDEL for this financial year.


The Cash FOT has been revised in line with the results at Q2 and it is now expected to be c. £62,279k by the end of March 2022.

The projected 2021/22 closing balance includes external PDC funding for the eradication of Dormitories £1,124k and Cyber Security scheme £190k.



Capital Programme

| Category | 2021/22 | | 2022/23 | 2023/24 | 2024/25 | 2025/26 | Total Programme Forecast |
|--------------|--------------|--------------|---------------|---------------|---------------|---------------|--------------------------|
| | YTD £000 | FOT £000 | Plan £000 | Plan £000 | Plan £000 | Plan £000 | |
| Therapeutic | 22 | - | 2,850 | 9,630 | 14,136 | 20,000 | 46,616 |
| EPR | - | 600 | 4,000 | 2,136 | - | - | 6,736 |
| Buildings | 3,290 | 7,228 | 5,924 | 4,668 | 4,500 | 2,000 | 24,320 |
| Transport | 182 | 280 | 370 | - | 30 | - | 680 |
| Equipment | 35 | 50 | 50 | 50 | 30 | - | 180 |
| IMST | 28 | 339 | 949 | 625 | 488 | - | 2,401 |
| Total | 3,557 | 8,497 | 14,143 | 17,109 | 19,184 | 22,000 | 80,933 |




POSITION SUMMARY 2021/22

| Capital Position to Date | Revised Plan | Actual | Variance |
|---|--------------|--------|---|
| In-month spend | 783 | 707 | (76) Amber |
| Cumulative spend | 3,630 | 3,557 | (73) Amber |
| Capital expenditure is <85% or >115% of plan for year to date | | | Amber |

| Capital Forecast Outturn | Original Plan | FOT | Variance |
|---|---------------|-------|---|
| Cumulative spend | 8,497 | 8,497 | 0 Green |
| Capital expenditure is <85% or >115% of plan for year to date | | | Green |

CAPITAL PROJECT PORTFOLIO - YEAR TO DATE POSITION



NARRATIVE

The current capital plan was revised in October 2021 to accommodate ICS request for £877k to support the CDEL system. Additional funding for EPR £600k and Cyber Security £190k was communicated in November 21 therefore the total capital available for 2021/22 has increased from £7,707 to £8,497k. This is expected to be spent by the end of financial year therefore Estates are reviewing all schemes to ensure the CDEL limit is achieved.

At the end of November 2021, the Trust reports a total Capital expenditure including accruals of £3,557k, which is £73k below the revised forecast outturn. This shortfall is due to scheduling reviews of some Estates schemes proposed to rectify CQC inspection defects. The rescheduling and review of the new Headquarters relocation also delayed planned expenditure over this period.

Successful delivery of the revised plan requires close monitoring over the coming weeks and months. Finance will be working closely with Estates to ensure key milestones are achieved and variances are communicated.